Mondrian Investment Partners LTD reduced its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 13.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 60,461 shares of the company’s stock after selling 9,586 shares during the period. Mondrian Investment Partners LTD’s holdings in Omnicell were worth $2,932,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. California Public Employees Retirement System increased its stake in Omnicell by 4.2% during the 2nd quarter. California Public Employees Retirement System now owns 81,200 shares of the company’s stock worth $3,500,000 after buying an additional 3,300 shares during the period. Northern Trust Corp increased its stake in Omnicell by 6.0% during the 2nd quarter. Northern Trust Corp now owns 515,757 shares of the company’s stock worth $22,230,000 after buying an additional 29,217 shares during the period. Kornitzer Capital Management Inc. KS increased its stake in Omnicell by 20.8% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 155,240 shares of the company’s stock worth $7,925,000 after buying an additional 26,700 shares during the period. Nationwide Fund Advisors increased its stake in Omnicell by 6.0% during the 2nd quarter. Nationwide Fund Advisors now owns 269,177 shares of the company’s stock worth $11,602,000 after buying an additional 15,222 shares during the period. Finally, Parametric Portfolio Associates LLC increased its stake in Omnicell by 20.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 174,763 shares of the company’s stock worth $7,532,000 after buying an additional 29,484 shares during the period. 99.61% of the stock is currently owned by hedge funds and other institutional investors.

In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the sale, the chief financial officer now directly owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Peter J. Kuipers sold 4,724 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.74, for a total transaction of $225,523.76. Following the completion of the sale, the vice president now directly owns 40,544 shares in the company, valued at $1,935,570.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,558 shares of company stock worth $1,330,230. Insiders own 3.77% of the company’s stock.

Shares of Omnicell, Inc. (NASDAQ:OMCL) opened at $50.55 on Friday. Omnicell, Inc. has a 52-week low of $32.70 and a 52-week high of $55.40. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08. The company has a market cap of $1,930.76, a P/E ratio of -459.55, a price-to-earnings-growth ratio of 4.04 and a beta of 0.71.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.42 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. During the same period in the prior year, the firm posted $0.40 EPS. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. equities research analysts anticipate that Omnicell, Inc. will post 0.12 earnings per share for the current year.

OMCL has been the topic of several recent research reports. Oppenheimer reaffirmed a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Thursday, October 19th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $60.00 target price on shares of Omnicell in a research note on Wednesday, December 13th. Craig Hallum reaffirmed a “buy” rating and set a $62.00 target price (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Zacks Investment Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Finally, BidaskClub downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $55.14.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/19/omnicell-inc-omcl-stake-lowered-by-mondrian-investment-partners-ltd.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.